Poolbeg Pharma yesterday announced a deal with the Israeli artificial intelligence (AI)-based biotech CytoReason to conduct a drug discovery programme aimed at identifying potential drug development candidates for the treatment of influenza. The move represents Poolbeg's second foray into AI-based
